A review of irbesartan in antihypertensive therapy: Comparison with other antihypertensive agents

Current Therapeutic Research - Clinical and Experimental

Volumn 62, Issue 7, 2001, Pages 505-523

  Waeber, Bernard ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Antihypertensive agents; Hypertension; Irbesartan

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; CANDESARTAN; ENALAPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; VALSARTAN;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0034926388     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(01)80050-3     Document Type: Article

References (33)

1. Evidence-based health policy-lessons from the Global Burden of Disease Study
2. The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure
3. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991
4. The impact of side effects on hypertension management: A Japanese survey
5. Perceived symptoms amongst hypertensive patients in routine clinical practice - A population-based study
6. Changes in antihypertensive therapy - The role of adverse effects and compliance
7. Assessing patient wellness: New perspectives on quality of life and compliance
8. Angiotensin II receptor antagonists
9. The new angiotensin II receptor antagonist, irbesartan: Pharmacokinetic and pharmacodynamic considerations
10. A review of the clinical experience with the angiotensin II receptor antagonist irbesartan
11. Safety of irbesartan in the treatment of mild to moderate systemic hypertension
12. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension
13. Dose-related efficacy of irbesartan for hypertension: An integrated analysis
14. Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension
15. Rate and extent of left ventricular hypertrophy regression: A comparison of angiotensin II blockade with irbesartan and beta-blockade
16. The antihypertensive efficacy and safety of irbesartan compared with amlodipine for the treatment of mild-to-moderate hypertension
17. Safety and efficacy of irbesartan in hypertensive patients with type II diabetes and proteinuria
18. A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension
19. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension
20. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension
21. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension
22. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan
23. Irbesartan results in superior blood pressure reduction vs valsartan
24. 1 receptor antagonists
25. Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay
26. 1-receptor mediated effects than does candesartan cilexetil as evidenced by higher plasma renin levels
27. Extent and duration of angiotensin II antagonistic activity of irbesartan and candesartan cilexetil
28. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension
29. Treating the individual hypertensive patient: Considerations on dose, sequential monotherapy and drug combinations
30. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo
31. 1-receptor blockers in hypertension and heart failure: Clinical experience and future directions
32. Stepped care for hypertension: Are the assumptions valid?
33. Angiotensin II receptor blockers: Equal or preferred substitutes for ACE inhibitors?